ASH 2018 | Alvocidib followed by cytarabine and mitoxantrone in MCL-1–dependent R/R AML
Joshua Zeidner
• 12 Dec 2018
In this interview, Joshua Zeidner, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the results of the Phase II Zella 201 study (NCT02520011) assessing the clinical response of alvocidib, in combination with cytarabine and mitoxantrone, in MCL-1–dependent, relapsed/refractory acute myeloid leukemia (AML) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Zeidner reveals that alvocidib given before cytarabine and mitoxantrone in MCL-1-dependent AML has clinical activity, particularly in those refractory to frontline therapy.
